

ORIGINAL ARTICLE / PRACA ORYGINALNA

Grażyna Gadomska¹, Klaudia Chałupnik², Katarzyna Stankowska², Joanna Boinska², Ewelina Drela², Barbara Ruszkowska-Ciastek², Monika Leszcz², Jacek Kubica³, Danuta Roś²

**ENDOTHELIAL PROGENITOR CELLS IN MYELOPROLIFERATIVE NEOPLASMS
– PRELIMINARY REPORT**

**KOMÓRKI PROGENITOROWE ŚRÓDBŁONKA W NOWOTWORACH
MIELOPROLIFERACYJNYCH – DONIESIENIA WSTĘPNE**

¹Department of Hematology and Malignant Diseases of Hematopoietic System,
Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland

Head of Department: dr hab. n. med. Jarosław Czyż

²Department of Pathophysiology, Nicolaus Copernicus University in Toruń,
Collegium Medicum in Bydgoszcz, Poland

Head of Department: prof. dr hab. n. med. Danuta Roś

³Department of Cardiology and Internal Medicine,
Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Poland

Head of Department: prof. dr hab. n. med. Jacek Kubica

S u m m a r y

The aim of this study was to assess the number of endothelial progenitor cells in patients with chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET). The study involved 21 patients (mean age 61.77) with myeloproliferative neoplasms, hospitalized and diagnosed at the Hematology Clinic of Dr. J. Biziel University Hospital No. 2 in Bydgoszcz, Poland.

Material and methods. The study group included 12 patients with ET, 5 with PV, 4 with CML. The control group consisted of 25 healthy volunteers, age- and sex- matched. The material for the study was venous blood collected from the elbow vein into tube containing K2EDTA.

The number of endothelial progenitor cells was measured with FACSCalibur flow cytometer (Becton Dickinson, San

Diego, USA) using monoclonal antibodies directed against antigens specific for endothelial progenitor cells (EPCs).

Results. We observed significantly increased number of EPCs in patients with myeloproliferative neoplasms (MPNs) in comparison to the control group. Detailed analysis showed slightly higher number of EPCs in patients with PV and ET than in the controls, but the differences were not statistically significant. The highest statistically significant number of EPCs was observed in patients with CML.

Conclusions. Increased number of EPCs in patients with myeloproliferative neoplasms may indicate increased angiogenesis in these diseases and participation of EPCs in the process of neovascularization.

S t r e s z c z e n i e

Celem niniejszej pracy była ocena liczby i funkcji komórek progenitorowych śródbłonka w przewlekłej białacze szpikowej (PBS), czerwienicy prawdziwej (CzP), nadpłytkowości samoistnej (NS). Badaniem objęto 21 pacjentów z nowotworami mieloproliferacyjnymi (średnia wieku 61,77), hospitalizowanych w Oddziale Klinicznym Hematologii i Chorób Rozrostowych Układu Krwiotwór-

czego Szpitala Uniwersyteckiego nr 2 im. Jana Bizieła w Bydgoszczy.

Materiał i metody. Badania przeprowadzono u 12 chorych na ET, 4 chorych na CML i 5 chorych na PV. Grupę kontrolną stanowiło 25 zdrowych ochotników. Materiałem do badań była krew pobrana w godzinach porannych z nakłucia żyły łokciowej do próbówki

zawierającej wersenian dwupotasowy (EDTA). Po inkubacji z odpowiednimi odczynnikami dokonana została analiza cytometryczna przy użyciu cytometru przepływowego FACS Calibur (Becton Dickinson, San Diego, USA) z zastosowaniem programu komputerowego CellQuest.

Wyniki. U chorych na przewlekle nowotwory mieloproliferacyjne stwierdzono istotnie statystyczną zwiększoną liczbę EPCs w porównaniu z grupą kontrolną. U chorych z PV i ET stwierdzono nieznacznie zwiększoną liczbę EPCs w porównaniu do grupy kontrolnej, a różnica ta

okazała się nieistotna statystycznie. Najwyższą liczbę EPCs stwierdzono u pacjentów z CML i różnica ta była istotna statystycznie.

Wnioski. Zwiększenie liczby EPCs w grupie chorych na przewlekle nowotwory mieloproliferacyjne świadczy o aktywacji procesów angiogenezy w tych nowotworach i prawdopodobnie czynnym udziale tych komórek w procesie nowotworzenia naczyń.

Key words: endothelial progenitor cells, myeloproliferative neoplasms

Słowa kluczowe: komórki progenitorowe śródbłonna, nowotwory mieloproliferacyjne

INTRODUCTION

Myeloproliferative disorders (MPDs), which were described in a 2008 World Health Organization (WHO) classification as 'myeloproliferative neoplasms' (MPNs), are a group of diseases characterized by clonal proliferation of one or more myeloid cell lines caused by genetic alterations of multipotent stem cells [1, 2]. 'Classic myeloproliferative neoplasms' include: chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).

The first concept of myeloproliferative neoplasms is credited to Dameshek who assumed that these diseases result from disturbances of mechanisms regulating normal hematopoiesis [3, 4]. Starting from the discovery of the Philadelphia chromosome (Ph) in 1960, and then thanks to research on glucose-6-phosphate dehydrogenase (G6PD) isoenzyme phenomenon conducted by Fiałkowska in the 70s of the last century and introduction of clonogenic assays by Bradley and Metcalf, all of the above proved that at the foundation of MPNs lies mutation of multipotential stem cells [3, 5].

Endothelial progenitor cells (EPCs), derived from bone marrow, represent a heterogeneous group of blasts capable of self-renewal, colony-forming and differentiation 'on demand' into functional cells [6, 7, 8]. EPCs were first described by Asahara et al. in 1997 [9]. This discovery changed the view on vasculogenesis. Previously it had been believed that new vessels arose from undifferentiated angioblasts or endothelial progenitor cells during embryogenesis. Research conducted by Asahara et al. showed that EPCs participate in postnatal vasculogenesis [9, 10]. Endothelial progenitor cells are secreted into the blood as a result of endothelial damage for example by inflammatory factors, cytokines, or circulating autoantibodies [11, 12].

Recent years have seen an increase in interest in the subject of participation of endothelial progenitor cells in the pathogenesis of solid tumors – their growth depends on the development of new vascular networks. The newly formed blood vessels supply sufficient amounts of oxygen and nutrients to the growing tumor. Studies of patients with non-small cell lung cancer showed an increased number of EPCs in the endothelial tubes of tumor capillaries [13]. Participation of EPCs in formation of tumor vessels was confirmed in several solid tumors such as malignant glioma, lung cancer and breast cancer [14, 15]. However, the involvement of EPCs in angiogenesis is still under investigation [15].

Hematological malignancies do not develop as a compact tumor mass, for which a vascularization is a critical factor for further growth, invasion and metastasis. Tumor cells in myeloproliferative neoplasms arise in bone marrow and in the absence of the bone marrow-blood barrier they penetrate various organs. Researchers found that in patients with multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and primary myelofibrosis there is an increased vascularization of bone marrow and increased expression of angiogenic factors such as VEGF, bFGF, GM-CSF, G-CSF, EPO, and PlGF SDF [16]. These cytokines, besides controlling the formation of blood vessels, can also affect hematopoiesis and bone marrow stromal cells [16, 17, 18].

The aim of this study was to assess the number of endothelial progenitor cells in patients with chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET).

MATERIAL AND METHODS

The study involved 21 patients (mean age 61.77) with myeloproliferative neoplasms, hospitalized and diagnosed at the Hematology Clinic of Dr. J. Biziel University Hospital No. 2 in Bydgoszcz, Poland. These patients were enrolled in the study at the time of the

diagnosis of MPNs and prior to the implementation of an appropriate treatment. The diagnosis was based on the diagnostic criteria of myeloproliferative neoplasms according to the WHO (2008) including: medical interview, physical examination and additional tests (complete blood count with peripheral blood smear, selected parameters of coagulation system, bone marrow biopsy with histopathological evaluation and cytogenetics). The study group included 12 patients with essential thrombocythemia (mean age 59.25), 5 with polycythemia vera (mean age 65) and 4 with chronic myeloid leukemia (mean age 66). The control group consisted of 25 healthy volunteers (mean age 42.8).

The study obtained the approval of the local Ethics Committee (KB 396/2010). Each studied person was informed about the purpose of the research and gave written consent.

The number of endothelial progenitor cells was measured with FACSCalibur flow cytometer (Becton Dickinson, San Diego, USA) using monoclonal antibodies directed against antigens specific for endothelial progenitor cells (EPCs). Acquired data were analyzed by using CellQuest software (Becton Dickinson).

The following monoclonal antibodies were used in this study: fluorescein isothiocyanate (FITC) – conjugated anti-CD31, PerCP-Cy5.5-conjugated anti-CD45, as well as APC-conjugated anti-CD34 antibody (all BD Biosciences, Pharmingen, San Diego, CA, USA), phycoerythrin (PE)-conjugated anti-CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany). Endothelial progenitor cells (EPCs) were defined as negative for the hematopoietic marker CD 45 and positive for the endothelial progenitor marker CD 133, and positive for the endothelial cell markers CD 31 and CD 34. At least 100 000 events were collected before analysis. TruCount tubes (BD Biosciences, San Jose, CA, USA) containing a calibrated number of fluorescent beads and `lyse-no-wash` procedures were used in the present study.

The statistical analysis was performed using Statistica 10 software (StatSoft®). Shapiro-Wilk test was used to assess the normality of distribution. Since the examined parameter showed a non-normal distribution, median (Me) and quartiles (lower - Q1 and upper - Q3) were used. Mann Whitney U test were used to compare the difference between groups. The p-values <0.05 were considered significant.

RESULTS

Table I shows the number of endothelial progenitor cells (EPCs) in MPNs patients and in the control

group. We observed significantly higher number of EPCs in patients with myeloproliferative neoplasms than in the controls.

Table I. Comparison of the number of endothelial progenitor cells (EPCs) in patients with myeloproliferative neoplasms and in the control group

Tabela I. Porównanie liczby komórek progenitorowych śródbłonna (EPCs) w grupie kontrolnej i chorych na nowotwory mieloproliferacyjne

Parameter Parametr	Study group Grupa badana n=21			Control group Grupa kontrolna n=25			p
	Me	Q1:Q3	Min-Max	Me	Q1:Q3	Min-Max	
EPCs/ μ L	0.97	0.51;2.83	0.00-8.96	0.51	0.31;1.02	0.00-1.53	0.035202

Table II. Number of endothelial progenitor cells (EPCs) in PV, ET and CML patients compared to the control group

Tabela II. Liczba komórek progenitorowych śródbłonna w grupie chorych na CzP, NS i PBS w porównaniu do grupy kontrolnej

EPCs/ μ l	PV CzP	ET NS	CML PBS	CONTROL GROUP Grupa kontrolna (C)	p
N	5	12	4	25	PV vs C p=0,09 ET vs C p=0,12 CML vs C p= 0.009513
ME	0.97	0.70	3.56	0.61	
Q1:Q3	0.41;2.34	0.41;2.59	1.73; 4.96	0.31;0.92	
Min-Max	0.10 – 8.96	0.00 – 6.01	0.92; 5.33	0.00 – 1.63	

Moreover, a detailed analysis in subgroups of patients with MPNs showed that a significantly higher number of EPCs was found in patients with CML than in the control group (Table II, Figure 1).




Fig. 1. Number of endothelial progenitor cells (EPCs) in patients with chronic myeloid leukemia CML compared to the control group

Ryc. 1. Porównanie liczby komórek progenitorowych śródbłonna (EPCs) w grupie kontrolnej i grupie chorych na przewlekłą białaczkę szpikową (PBS)

DISCUSSION

Angiogenesis is a multistep process involved in tumor growth and metastasis formation [19]. Angiogenesis is regulated by many angiogenic factors, among them: vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), granulocyte colony-stimulating factor (G-CSF), interleukin-1 (IL-1), interleukin-6 (IL-6), angiopoietin 1 and 2 [20].

Recently there has been an increased interest in the role of endothelial progenitor cells in the context of angiogenesis, especially in hematological malignancies.

Endothelial progenitor cells (EPCs) represent a heterogeneous group of blasts capable of self-renewal, colony-forming and differentiation 'on demand' into functional cells. It has been shown that several factors may lead to release of EPCs from bone marrow into circulation, where EPCs migrate to the site of injury in vascular system [8, 21]. However, mechanism of EPCs migration and homing remains unclear. It is known that the most potent chemoattractant for EPCs is the stromal cell-derived factor-1 (SDF-1) [21].

The aim of this study was to assess the number of endothelial progenitor cells in patients with myeloproliferative neoplasms. Analysis of the results obtained in the present study showed that the number of EPCs was significantly increased in patients with myeloproliferative neoplasms in comparison to the control group. The highest number of EPCs was observed in patients with CML. However, in patients with PV and ET the number of EPCs was slightly increased compared to the control group but the differences were not statistically significant.

Rafat et al. examined the relationship between the number of EPCs and angiogenesis in patients with malignant gliomas. Researchers observed significantly higher mobilization of EPCs in these patients than in the control group. In addition, Rafat et al. showed significant correlations between EPCs number and serum level of VEGF, as well as between EPCs and vessel density, and a negative correlation between the number of EPCs and tumor size. Patients with malignant gliomas and high density of tumor blood vessels have a higher level of EPCs than patients with a low vessel density [22]. The relationship between the number of EPCs and angiogenesis were also reported by Arbab et al., Lin et al., and Deng et al. Researchers have demonstrated that patients with non-small cell lung cancer, breast cancer and hepatocellular

carcinoma have a significantly higher level of EPCs in comparison with the control group. Moreover, they found significant correlations between EPCs number and tumor microvessel density, and between EPCs and VEGF level in these patients [13, 14, 15, 23].

The assessment of angiogenesis process is based primarily on measurement of microvessel density in bone marrow and on the evaluation of VEGF concentration. However, for the assessment of bone marrow microvessel density, invasive diagnostic procedures such as biopsy of the tumor or bone marrow are necessary. There is an ongoing search for non-invasive, effective research methods to assess the intensity of angiogenesis in the course of many diseases, including in myeloproliferative neoplasms [8, 24].

The present study showed slightly higher number of EPCs in patients with PV and ET than in the controls, but the differences were not statistically significant.

Alonci et al. observed significantly elevated EPCs number in patients with PV. Leibundgut et al. reported significantly increased number of endothelial progenitor cells in patients with PV and ET [25, 26].

Summing up, results obtained in the present study, as demonstrated by the higher number of EPCs found in patients with myeloproliferative neoplasms compared to the controls, indicate that endothelial progenitor cells are mobilized from bone marrow into peripheral blood. It is known from the literature that EPCs promote angiogenesis [15]. However, due to the small size of the group of patients with MPNs and the uneven distribution of the number of patients with various myeloproliferative neoplasms, current results are considered preliminary and research is being continued on a larger number of patients with MPNs.

CONCLUSIONS

We observed significantly higher number of EPCs in patients with myeloproliferative neoplasms than in the control group; the highest number of EPCs was noted in patients with CML.

Increased number of EPCs in patients with myeloproliferative neoplasms may indicate increased angiogenesis in these diseases and participation of EPCs in the process of neovascularization.

REFERENCES

1. Prochorec-Sobieszek M. Nowotwory mielodysplastyczne/mieloproliferacyjne - nowości i problemy diagnostyczne. *Hematologia* 2010; 1 (3): 185-194.
2. Szumowska A., Galar M., Kłoczko J. Haemostasis disturbances in polycythemia vera and essential thrombocythemia. *Acta Haematol Pol* 2012; 43 (2b): 187-191.
3. Vainchenker W., Delhommeau F., Constantinescu SN. et al. New mutations and pathogenesis of myeloproliferative neoplasms. *Blood* 2011; 118 (7): 1723-1735.
4. Tefferi A., Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system. *Best Pract Res Clin Haematol* 2006; 19 (3): 365-385.
5. Hellmann A. Rozpoznawanie i możliwości leczenia zespołów mieloproliferacyjnych. *Pol Arch Med Wewn* 2008; 118 (12): 756-760.
6. Hrycek E., Wojakowski W. The influence of the biological age on function of endothelial progenitor cells. *Kardiologia* 2010; 68 (suppl. 5): 405-411.
7. Góra - Tybor J., Krawczyńska A. Circulating endothelial cells - a noninvasive angiogenesis marker. *Acta Haematol Pol* 2007; 38 (2): 195-202.
8. Partyka Ł., Siwiec K., Niżankowski R., et al. Endothelial progenitor cells (EPCs) in therapy. *Acta Angiol* 2003; 9 (2): 53-62.
9. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999; 85 (3): 221-228.
10. Wróbel T. Angiogenesis in haematologic malignancies. *Acta Haematol Pol* 2004; 35 (4): 493-504.
11. Krawczyk A., Izdebska M., Grzanka A. The influence of hyperglycemia on functions of endothelial progenitor cells. *Pol Merkuriusz Lek* 2009; 26 (153): 245-247.
12. Brzozowski A., Dmoszyńska A. Bone marrow-derived Endothelial Progenitor Cells: the biology, functions and clinical applications. *Acta Haematol Pol* 2004; 35 (2): 177-187.
13. Janic B, Arbab AS. The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. *ScientificWorldJournal* 2010; 10: 1088-1099.
14. Lin EH., Jiang Y., Deng Y., et al. Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: "seed and soil" theory revisited. *Gastrointest Cancer Res* 2008; 2 (4): 169-174.
15. Sun XT., Yuan XW., Zhu HT., et al. Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma. *World J Gastroenterol* 2012; 18 (35): 4925-4933.
16. Wojtukiewicz MZ., Sierko E. The approach to antiangiogenic therapy in cancer patients. *Onkol Prak Klin* 2009; 5: 1-14.
17. Banyś A., Bulaś L., Długosz E., et al. Angiogeneza w chorobie nowotworowej. *Farm Pol* 2009; 65 (4): 247-250.
18. Medinger M., Mross K. Clinical trials with anti-angiogenic agents in hematological malignancies. *J Angiogenes Res* 2010; 2: 1-11.
19. Mizia - Malarz A., Sobol G., Woś H. Angiogenesis in the chronic inflammatory diseases and malignancies. *Pol Merk Lek* 2008; 25 (141): 185-189.
20. Jurczyszyn A., Wolska - Smoleń T., Skotnicki AB. Angiogenesis in normal and neoplastic hematopoiesis. *Adv Clin Exp Med* 2003; 12 (4): 489-496.
21. Kapielko - Słowiek K., Urbaniak - Kujda D., Wołowicz D., et al. Serum concentration of angiogenin in patients with acute lymphoblastic leukemia and acute myeloid leukemia and its relationship with clinical course of the disease. *Acta Haematol Pol* 2008; 39 (1): 63-71.
22. Rafat N., Beck GCh., Schulte J., et al. Circulating endothelial progenitor cells in malignant gliomas. *J Neurosurg* 2010; 112 (1): 43-49.
23. Wideł SM., Wideł M. Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. *Postepy Hig Med Dosw* 2006; 60: 453-470.
24. Beerepoot LV., Mehra N., Vermaat JS., et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. *Ann Oncol*; 2004; 15 (1): 139-145.
25. Oppliger Leibundgut E., Horn MP., Brunold C., et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. *Hematologica* 2006; 91 (11): 1465-1472.
26. Alonci A., Allegra A., Bellomo G., et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. *Hematol Oncol* 2008; 26 (4): 235-239.

Address for correspondence:

Katarzyna Stankowska
Department of Pathophysiology, Nicolaus Copernicus
University in Toruń
Collegium Medicum in Bydgoszcz
Marii Skłodowskiej-Curie 9
85-094 Bydgoszcz, Poland
e-mail: stankowska_katarzyna@wp.pl
tel. 52/585-35-91
fax 52/585-35-95

Received: 20.01.2014

Accepted for publication: 30.04.2014